World Alzheimer's Day 2021: The Power of Knowledge

World Alzheimer's Day is an international campaign organised by Alzheimer's Disease International to raise awareness and highlight issues faced by people affected by dementia. It takes place every year on September 21st and is the focus of World Alzheimer's Month.

Dementia is one of the biggest challenges we face, with nearly 50 million people living with dementia worldwide. Yet 2 out of every 3 people globally believe there is little or no understanding of dementia in their countries.The impact of World Alzheimer's Month is growing, but the stigmatisation and misinformation that surrounds dementia remains a global problem. To tackle this challenge, we need to collaborate and share best practice with one another.

In support of this year’s theme – ‘Know dementia, know Alzheimer's’ - Elsevier presents a curated, open access collection of over 70 journal articles and book chapters focused on shining a light on the warning signs of dementia and the importance of a timely diagnosis.

Elsevier, Archives of Gerontology and Geriatrics, Volume 89, July - August 2020
Background: Falls in older adults, notably those with Alzheimer's dementia (AD), are prevalent. Vision and balance impairments are prominent falls risk factors in older adults. However, recent literature in the cognitively impaired suggests that executive function (EF) is important for falls risk assessments. The study objectives were to: 1) to compare balance among people with AD, healthy older adults (OA), and healthy young adults (YA) and 2) to quantify the interaction of visual acuity and EF on postural stability. Methods: We recruited 165 individuals (51 YA, 48 OA, and 66 AD).
Elsevier, Steroids, Volume 156, April 2020
Background: The nuclear factor erythroid2-related factor2 (Nrf2), a chief transcriptional regulator of antioxidant response element (ARE), is considered a promising target for the prevention of Alzheimer's disease (AD). Vitamin D has been recognized to have a crucial role in improving AD cognitive functions. The present study was conducted to evaluate the effects of active vitamin D analogue, Maxacalcitol, on Keap1-Nrf2 signaling pathway in experimental Alzheimer's disease in rats.
Elsevier, Public Health, Volume 181, April 2020
Objectives: People with life-limiting diseases such as dementia are living longer. How to improve the quality of life of those living with dementia is an important challenge for society. Continuity maintenance in older adulthood is a psychosocial adaptation strategy by searching for preference and familiarity, making a sense of connection, and creating coherence. Continuity maintenance is a useful concept for effective dementia care, which could bring psychosocial benefits. This review investigates effective ways of continuity maintenance for people with dementia (PWD).
Elsevier, Journal for Nurse Practitioners, Volume 16, March 2020
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and a leading cause of dementia in the elderly. AD initially presents as mild cognitive impairment (MCI); later, as AD progresses, memory and cognition are destroyed, preventing the ability to carry out activities of daily living. The primary care provider may be the first to suspect MCI, and screening tests can help with diagnosis. Development of drugs for cognitive decline in AD has been slow; however new therapies are in the pipeline and discovery of biomarkers make early diagnosis and future treatment of AD hopeful.
Elsevier, Peptides, Volume 125, March 2020
Glucose-dependent Insulinotropic polypeptide (GIP) is a peptide hormone of the incretin family. It has growth factor properties and can re-activate energy utilization. In progressive neurodegenerative disorders such as Alzheimer's and Parkinson's disease, energy utilization is much reduced, and GIP has the potential to reverse this. Furthermore, GIP can reduce the inflammation response in the brain and reduce levels of pro-inflammatory cytokines. Tests in animal models of Alzheimer's and Parkinson's disease show good neuroprotective effects.
Elsevier, Journal of the American Academy of Dermatology, Volume 82, February 2020
Elsevier,

Dementia Rehabilitation, October 2020, Pages 227-261

This book chapter advances SDGs 3 and 17 by reviewing research on a range of rehabilitation programmes aiming to improve the functional independence of people with dementia, such as specialist-led or multimodal rehabilitation, cognitive rehabilitation, function-focused care, and reablement.
Elsevier,

Dementia Rehabilitation, October 2021, Pages 57-79

This book chapter advances SDGs 3 and 17 by outlining the common physical impairments found in people living with dementia, as well as evidence for treatments to maintain or improve physical function and prevent falls, in both community and residential settings.
Elsevier,

Dementia Rehabilitation, October 2020, Pages 35-56

This book chapter advances SDGs 3 and 17 by reviewing behavioral interventions and strategies for spoken communication for people with dementia and their communication partners.
Elsevier,

Diagnosis and Management in Dementia, Volume 1, August 2020, Pages 681-693

This book chapter advances SDGs 3 and 17 by reviewing pathological and functional outcomes of both preventative and therapeutic environmental enrichment on commonly used mouse models of amyloid pathology.

Pages